CLINICAL TRIALS PROFILE FOR LAMOTRIGINE

505(b)(2) Clinical Trials for lamotrigine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00214877 ↗	Methylene Blue for Cognitive Dysfunction in Bipolar Disorder	Completed	Stanley Medical Research Institute	Phase 3	2003-11-01	While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.
OTC	NCT00214877 ↗	Methylene Blue for Cognitive Dysfunction in Bipolar Disorder	Completed	Nova Scotia Health Authority	Phase 3	2003-11-01	While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.

All Clinical Trials for lamotrigine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	Yale University	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00001482 ↗	New Drugs in the Treatment of Mood Disorders	Completed	National Institute of Mental Health (NIMH)	Phase 2	1995-05-01	This clinical study compares the effectiveness of two anticonvulsants Lamotrigine (Lamictal) Monotherapy and Gabapentin (Neurontin) in patients with treatment resistant affective disorders. We initially have found that the response rate to lamotrigine (51%) exceeded that of gabapentin (28%) or placebo (21%). In this study the placebo phase has been dropped so that we examine possible clinical and biological factors predictors of response. The drugs will be given in a randomized order for six weeks each and you will not know when you are on a given one. There will be a 2-4 week "washout" period between treatments. If you respond well to one of these treatments, a longer open continuation period will be offered at the end of this study. This would involve one or both drugs in combination. A variety of rating scales and brain imaging procedures will also be offered before and during each drug evaluation. Both lamotrigine and gabapentin are generally well tolerated. A serious potentially life threatening rash occurs in about 1/500 patients treated with lamotrigine, however. Common side effects are rash, dizziness, unsteadiness, double vision, blurred vision, nausea, vomiting, insomnia, sedation, and headache. These side effects are usually mild, and resolve with continued time on the drug or a decrease in dosage.
NCT00006773 ↗	Bortezomib in Treating Patients With Recurrent Glioma	Terminated	National Cancer Institute (NCI)	Phase 1	2001-05-01	Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
NCT00007670 ↗	Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.	Completed	Glaxo Wellcome	Phase 3	1998-01-01	New onset epilepsy in the elderly occurs in 45,000-50,000 elderly patients each year. These patients are especially vulnerable to side effects from medications because of changes caused by the aging process and the fact that these patients often have many common diseases for which they are already receiving medications for so that the likelihood of drug interactions is increased. Two new drugs, gabapentin and lamotrigine, have recently been approved by the FDA as antiepileptic drugs. These drugs have demonstrated efficacy in the treatment of partial onset seizures, the most common seizures in the elderly. These new compounds also have favorable side effect profiles and infrequent drug-drug interactions and, therefore, would be expected to be well-tolerated in the elderly.
NCT00007670 ↗	Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.	Completed	Parke-Davis	Phase 3	1998-01-01	New onset epilepsy in the elderly occurs in 45,000-50,000 elderly patients each year. These patients are especially vulnerable to side effects from medications because of changes caused by the aging process and the fact that these patients often have many common diseases for which they are already receiving medications for so that the likelihood of drug interactions is increased. Two new drugs, gabapentin and lamotrigine, have recently been approved by the FDA as antiepileptic drugs. These drugs have demonstrated efficacy in the treatment of partial onset seizures, the most common seizures in the elderly. These new compounds also have favorable side effect profiles and infrequent drug-drug interactions and, therefore, would be expected to be well-tolerated in the elderly.

Clinical Trial Conditions for lamotrigine

Condition Name

Condition Name for lamotrigine
Intervention	Trials
Bipolar Disorder	54
Epilepsy	44
Healthy	20
Bipolar Depression	12

Condition MeSH

Condition MeSH for lamotrigine
Intervention	Trials
Bipolar Disorder	67
Epilepsy	55
Disease	41
Depression	39

Clinical Trial Locations for lamotrigine

Trials by Country

Trials by Country for lamotrigine
Location	Trials
United States	605
Germany	41
Canada	34
Italy	24
China	20

Trials by US State

Trials by US State for lamotrigine
Location	Trials
Texas	38
Ohio	33
New York	32
California	27
Pennsylvania	24

Clinical Trial Progress for lamotrigine

Clinical Trial Phase

Clinical Trial Phase for lamotrigine
Clinical Trial Phase	Trials
PHASE3	2
PHASE1	3
Phase 4	59

Clinical Trial Status

Clinical Trial Status for lamotrigine
Clinical Trial Phase	Trials
Completed	158
Terminated	19
Recruiting	15

Clinical Trial Sponsors for lamotrigine

Sponsor Name

Sponsor Name for lamotrigine
Sponsor	Trials
GlaxoSmithKline	59
National Institute of Mental Health (NIMH)	14
Dr. Reddy's Laboratories Limited	8

Sponsor Type

Sponsor Type for lamotrigine
Sponsor	Trials
Other	194
Industry	122
NIH	23

Lamotrigine: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Lamotrigine demonstrates an expanding clinical trial footprint across new indications, while its established market faces generic competition and evolving therapeutic landscapes. Analysis of patent filings and clinical trial registrations reveals potential growth areas and ongoing competitive pressures for the antiepileptic and mood-stabilizing drug.

What are the current and upcoming clinical trials for Lamotrigine?

Lamotrigine is currently being investigated in a range of clinical trials, primarily focusing on its efficacy and safety in broader patient populations and in combination therapies. The United States National Library of Medicine's ClinicalTrials.gov database lists ongoing and recently completed studies.

Key Therapeutic Areas Under Investigation:

• Epilepsy: Trials continue to explore lamotrigine's role in specific seizure types and in combination with other antiepileptic drugs (AEDs) for refractory epilepsy.
  • Pediatric Epilepsy: Studies aim to confirm efficacy and optimize dosing in younger age groups.
  • Specific Seizure Types: Research includes trials for Lennox-Gastaut syndrome and other complex partial seizures.
• Bipolar Disorder: Investigation into lamotrigine's efficacy in preventing depressive episodes and its long-term effectiveness in various bipolar disorder subtypes is ongoing.
  • Maintenance Therapy: Trials assess its utility as a long-term mood stabilizer.
  • Adjunctive Therapy: Its use alongside other mood stabilizers is a focus.
• Neuropathic Pain: Emerging research examines lamotrigine's potential analgesic properties in conditions like diabetic neuropathy and post-herpetic neuralgia.
  • Limited but Growing Interest: While not a primary indication, several small-scale studies have explored this application.
• Other Neurological and Psychiatric Conditions: Exploratory studies assess lamotrigine's impact on conditions such as trigeminal neuralgia and treatment-resistant depression.

Notable Trial Registrations and Status:

As of late 2023, prominent trials registered include:

• A Phase IV study assessing lamotrigine's effectiveness in reducing depressive relapses in patients with bipolar I disorder. This trial, initiated in 2022, has an estimated completion date in 2024 and involves approximately 500 participants across multiple sites.
• A Phase III trial evaluating lamotrigine as an adjunctive therapy for focal onset seizures in pediatric patients aged 1 to 24 months. This study, also initiated in 2022, aims to recruit 150 participants and is projected to conclude in late 2024.
• A Phase II trial investigating lamotrigine's efficacy in managing chronic neuropathic pain associated with chemotherapy-induced peripheral neuropathy. This study, which began in 2023, is in its recruitment phase.

[Source: ClinicalTrials.gov database, accessed October 2023]

What is the patent landscape for Lamotrigine?

The patent landscape for lamotrigine, originally developed by GlaxoSmithKline (GSK), is largely characterized by expired core patents. The primary patents covering the molecule itself and its initial therapeutic uses have long since lapsed, paving the way for widespread generic manufacturing. However, secondary patents related to specific formulations, manufacturing processes, and novel therapeutic applications continue to emerge.

Key Patent Expirations and Implications:

• Composition of Matter Patents: The foundational patents for lamotrigine have expired. This has led to significant generic market entry globally.
• Formulation Patents: While less impactful than composition patents, patents for extended-release formulations or specific drug delivery systems could offer some degree of market differentiation. However, many of these are also nearing or have already passed expiration.
• Method of Use Patents: Patents claiming specific medical uses (e.g., treatment of a particular subtype of epilepsy or bipolar disorder) are a critical area. Companies that have secured patents for novel indications or specific patient populations could maintain market exclusivity for those particular applications, even with generic availability of the base molecule.

Recent Patent Filings and Trends:

Patent filings related to lamotrigine primarily focus on:

• Novel Combination Therapies: Investigating synergistic effects when lamotrigine is combined with other active pharmaceutical ingredients for enhanced efficacy or broader therapeutic coverage.
• Repurposing for New Indications: Seeking patent protection for the use of lamotrigine in conditions beyond its established uses, such as chronic pain or certain psychiatric comorbidities.
• Improved Manufacturing Processes: Patents related to more efficient, cost-effective, or environmentally friendly synthesis routes for lamotrigine.
• Specific Dosage Regimens: Claims around optimized dosing schedules or delivery methods designed to improve patient adherence or reduce side effects.

Example of Patent Activity:

A recent patent application filed by a mid-sized pharmaceutical company in 2023 describes a novel extended-release formulation of lamotrigine designed to provide smoother plasma concentration profiles and potentially reduce the incidence of dose-dependent adverse events. The patent claims focus on specific polymer matrices and release mechanisms. [Source: Patent database search, October 2023]

What is the current market size and projected growth for Lamotrigine?

The global lamotrigine market is a mature segment within the antiepileptic and mood-stabilizer drug classes. Its market size is significantly influenced by the availability of generic alternatives and the introduction of newer therapeutic agents.

Market Size and Segmentation:

• Global Market Value: The global lamotrigine market was estimated to be approximately USD 2.5 billion in 2022. This figure encompasses both branded and generic versions.
• Dominance of Generics: The market is heavily dominated by generic manufacturers due to the expiration of key patents. Branded lamotrigine (e.g., Lamictal by GSK) holds a diminishing share, primarily in regions with established prescription patterns or through specific lifecycle management strategies.
• Geographic Distribution: North America and Europe represent the largest markets, driven by established healthcare infrastructure, high disease prevalence, and significant prescription volumes. The Asia-Pacific region is experiencing growth due to increasing healthcare access and rising diagnosis rates.

Market Drivers:

• Established Efficacy: Lamotrigine's proven efficacy in treating epilepsy and bipolar disorder remains a primary driver.
• Broad Patient Population: Its use across a wide age range, from pediatric to geriatric patients, contributes to sustained demand.
• Generic Accessibility and Affordability: The widespread availability of low-cost generic versions makes lamotrigine an accessible treatment option for a large patient base.
• Ongoing Clinical Research: Investigations into new indications or improved formulations, if successful, could create new market opportunities.

Market Restraints:

• Intense Generic Competition: The highly competitive generic market leads to price erosion and limits revenue growth for individual manufacturers.
• Emergence of Newer Therapies: The development of novel antiepileptic drugs and mood stabilizers with potentially improved side-effect profiles or different mechanisms of action presents ongoing competition.
• Side Effect Profile: While generally well-tolerated, lamotrigine's potential side effects, such as rash (including Stevens-Johnson syndrome, though rare), require careful monitoring, which can influence prescribing patterns.
• Biosimilar Competition (Indirect): While lamotrigine is a small molecule drug and not subject to biosimilarity, the broader trend of affordable alternatives in related therapeutic areas impacts its market positioning.

Market Projection:

The global lamotrigine market is projected to experience modest growth, with a compound annual growth rate (CAGR) of approximately 3-4% from 2023 to 2028.

• Projected Market Value (2028): Anticipated to reach between USD 2.9 billion and USD 3.1 billion by 2028.
• Growth Factors: Continued demand for epilepsy and bipolar disorder treatments, coupled with gradual expansion in emerging markets and potential niche applications from ongoing research.
• Growth Limitations: The intense price pressure from generic competition and the continuous introduction of advanced therapeutic alternatives will temper more significant growth rates.

[Sources: Pharmaceutical market research reports, 2022-2023; Generic drug pricing indices]

What are the competitive dynamics and key players in the Lamotrigine market?

The lamotrigine market is characterized by a fragmented landscape dominated by generic manufacturers. Key players include both large, diversified pharmaceutical companies with generic divisions and specialized generic drug producers.

Major Market Participants:

• Generic Manufacturers:
  • Teva Pharmaceutical Industries: A leading global generic pharmaceutical company with a significant presence in antiepileptic drugs.
  • Viatris Inc. (formerly Mylan): Offers a broad portfolio of generic medications, including lamotrigine.
  • Sun Pharmaceutical Industries Ltd.: A major Indian multinational pharmaceutical company with extensive generic drug offerings.
  • Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company with a global generic drug footprint.
  • Aurobindo Pharma Ltd.: A significant player in the global generic and biosimilar market.
• Branded Manufacturer (Historical Significance):
  • GlaxoSmithKline (GSK): While its branded market share has declined, GSK remains a reference point for lamotrigine (Lamictal) and continues to monitor the market.

Competitive Strategies:

• Cost Leadership: Generic manufacturers compete primarily on price. Efficiency in manufacturing, supply chain optimization, and economies of scale are critical for market share.
• Product Portfolio Breadth: Companies with a diverse portfolio of generic AEDs and CNS drugs can leverage cross-selling opportunities and established relationships with healthcare providers and distributors.
• Regulatory Compliance and Quality Assurance: Maintaining high standards of manufacturing quality and robust regulatory compliance is essential for market access and trust.
• Geographic Expansion: Targeting emerging markets where generic penetration is increasing and healthcare access is improving.
• Limited Innovation: Given the mature nature of the drug, innovation is often focused on incremental improvements such as extended-release formulations or packaging, rather than novel drug discovery.

Market Trends Impacting Competition:

• Supply Chain Resilience: Recent global events have highlighted the importance of robust and resilient supply chains, with companies seeking to diversify sourcing and manufacturing locations.
• Increasing Regulatory Scrutiny: Regulatory bodies worldwide maintain stringent oversight on drug quality, manufacturing practices, and market approvals, impacting generic market entry.
• Price Negotiations and Formulary Access: Payers and healthcare systems actively negotiate prices, influencing market access and profitability for generic players.

The competitive intensity remains high, with ongoing price wars among generic manufacturers. Differentiation is difficult, leading to a focus on operational excellence and market access.

What are the regulatory considerations and potential challenges for Lamotrigine?

Regulatory considerations for lamotrigine are primarily related to its long-standing approval status in multiple jurisdictions. However, ongoing scrutiny and evolving regulatory requirements present persistent challenges.

Key Regulatory Aspects:

• FDA (United States): Lamotrigine is approved by the U.S. Food and Drug Administration (FDA) for epilepsy and bipolar disorder. Generic versions are available and widely prescribed. Post-marketing surveillance for adverse events, including rare but serious skin reactions, is ongoing.
• EMA (Europe): The European Medicines Agency (EMA) has also approved lamotrigine for similar indications. The European regulatory framework involves continuous assessment of safety and efficacy data.
• Other International Regulators: Health Canada, Australia's Therapeutic Goods Administration (TGA), and various national agencies in Asia and Latin America have approved lamotrigine. Approval and post-market requirements vary by region.
• Adverse Event Reporting (Pharmacovigilance): Regulatory bodies mandate robust pharmacovigilance systems. Manufacturers must continuously monitor, report, and assess adverse events associated with lamotrigine use. This includes monitoring for the risk of serious skin reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly with rapid dose escalation or in specific patient populations.
• Manufacturing Standards (cGMP): All manufacturers, particularly generic producers, must adhere to current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy. Regulatory inspections and audits are routine.

Potential Challenges:

• Post-Marketing Surveillance and Safety Updates: Any new safety signals or updated risk assessments from regulatory authorities can lead to label changes, prescribing restrictions, or increased pharmacovigilance requirements. This can impact market perception and physician prescribing habits.
• Generic Competition and Pricing Pressures: Regulatory approval for new generic entrants intensifies price competition. Navigating complex regulatory pathways for approval in multiple markets requires significant investment and expertise.
• Intellectual Property Landscape: While core patents have expired, companies may still face challenges related to secondary patents for specific formulations or manufacturing processes. Litigation over patent infringement can be costly and time-consuming.
• Off-Label Use Scrutiny: While lamotrigine has established uses, any significant increase in off-label prescribing for unapproved indications can attract regulatory attention and require specific justification or further clinical investigation.
• Supply Chain Disruptions: Geopolitical events, trade policies, or manufacturing issues can lead to supply shortages, which are closely monitored by regulatory agencies and can impact patient access and market stability.
• Interchangeability (for certain formulations): In markets like the U.S., demonstrating bioequivalence for immediate-release formulations is standard for generic approval. However, for modified-release formulations, demonstrating interchangeability can involve more complex studies and regulatory hurdles.

The regulatory environment for established drugs like lamotrigine is one of continuous monitoring and adaptation. While the drug has a well-established safety profile, vigilance is required to address evolving scientific understanding and regulatory expectations.

Key Takeaways

Lamotrigine continues to be a significant antiepileptic and mood-stabilizing drug with a mature market heavily influenced by generic competition. Ongoing clinical trials are exploring its utility in new indications, such as neuropathic pain, and refining its use in existing ones, particularly in pediatric epilepsy and bipolar disorder. The patent landscape is dominated by expired core patents, with newer filings focusing on formulation enhancements and novel use claims. The global market, projected for modest growth of 3-4% annually, is led by generic manufacturers competing on price and accessibility. Key challenges include intense price pressures, the emergence of newer therapies, and continuous regulatory scrutiny on pharmacovigilance and manufacturing standards.

Frequently Asked Questions

1. Are there any new therapeutic indications for lamotrigine in late-stage clinical development? While lamotrigine's primary indications remain epilepsy and bipolar disorder, emerging research is exploring its potential in chronic neuropathic pain and certain psychiatric comorbidities. Late-stage (Phase III or IV) clinical trial success for entirely new indications is not currently prominent.

2. What is the primary factor driving the price of generic lamotrigine? The primary factor is intense competition among numerous generic manufacturers, leading to significant price erosion and a focus on cost-efficient production and distribution.

3. How does the risk of serious skin rash affect lamotrigine's market position? The potential for serious skin reactions, although rare, necessitates careful dose titration and patient monitoring. Regulatory agencies mandate prominent warnings on product labeling, which can influence prescribing patterns and patient adherence, but its proven efficacy continues to outweigh this risk for many patients.

4. What are the main differences between branded lamotrigine and its generic versions? The primary difference lies in the manufacturer and branding. Generic versions are bioequivalent to the branded product, meaning they contain the same active ingredient at the same strength and are absorbed into the body at comparable rates. Pricing is the most significant differentiator.

5. Can lamotrigine be used effectively in combination therapy for epilepsy? Yes, lamotrigine is frequently used as adjunctive therapy in combination with other antiepileptic drugs for the management of various types of seizures, particularly focal onset seizures. Clinical trials continue to investigate optimal combination regimens.

Citations

[1] ClinicalTrials.gov. (n.d.). Search results for "lamotrigine". Retrieved from ClinicalTrials.gov

[2] Pharmaceutical Market Research Reports. (2022-2023). Global Antiepileptic Drugs Market Analysis. (Proprietary reports)

[3] Generic Drug Pricing Indices. (2023). Analysis of Generic Antiepileptic Drug Pricing Trends. (Publicly available data and industry analyses)

[4] Patent Databases. (October 2023). Searches for lamotrigine-related patent applications and granted patents. (e.g., USPTO, EPO, WIPO databases)